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Background
Pancreatic enzyme supplements are standard therapy for fat malabsorption in patients with exocrine pancreatic insufficiency. The FDA determined that published data are insufficient to support the efficacy and safety of these agents.
Aim
To determine if pancreatic enzyme supplements are: (i) superior to placebo for treating fat malabsorption and (ii) superior to other supplements based on randomized cross-over trials.
Methods
A computer-assisted search of MEDLINE and EMBASE was performed to identify relevant studies. Data extraction on study design, improvement in coefficient of fat absorption, diarrhoea and adverse events using prespecified forms.
Results
A total of 12 manuscripts met inclusion criteria. Most studies (10 ⁄ 12) compared pancreatic enzyme supplements that used different delivery systems, while using similar quantities of enzymes. These studies found no consistent difference in fat malabsorption or gastrointestinal symptoms between different active treatments. Two small placebo-controlled trials (n = 65 patients) demonstrate that pancreatic enzyme supplements are superior to placebo for fat absorption. Data are inadequate to determine if pancreatic enzyme supplements lead to weight gain or improvement in diarrhoea.
Conclusions
Based on data from randomized cross-over trials, pancreatic enzyme supplements appear to improve fat malabsorption. No specific branded product or specific delivery system is superior for treatment of fat malabsorption in patients with exocrine pancreatic insufficiency.
INTRODUCTION
In 2004, the FDA reported that published randomizedcontrolled trial (RCT) data on pancreatic enzyme supplements were insufficient to support their efficacy and safety. Furthermore, the FDA report on this topic noted that ''currently marketed pancreatic enzyme preparations differ in their composition, enzymatic activities, formulation, stability, and bioavailability. These differences have led to highly variable pancreatic enzyme preparation quality and therapeutic performances … and to unacceptable variability in … quality and therapeutic performance. '' 1 With this announcement, the FDA stated that manufacturers of pancreatic enzyme supplements would need to perform new RCTs and to submit these data as part of New Drug Applications (NDA) to continue to market specific pancreatic enzyme supplements. Pancreatic enzyme supplementation is the 'standard of care' for fat malabsorption among patients with exocrine pancreatic insufficiency, including patients with cystic fibrosis (CF) and alcohol-associated chronic pancreatitis. Our previous systematic review 2 demonstrated that only 4 randomized, parallel-design trials of pancreatic enzyme supplements have been performed and concluded that enzyme supplementation is more likely to improve coefficient of fat absorption (CFA) compared with placebo and that enzyme supplementation improved steatorrhoea. However, enzyme supplementation did not resolve fat malabsorption or steatorrhoea and trials reported very little data on adverse events. Furthermore, important differences in study design, including pancreatic enzyme dosage and measurement of CFA, prevented comparisons of different agents. We also noted that these RCTs did not assess important quality control issues identified by the FDA: (i) the 'shelf-life' or potency of these agents over 12 months; or (ii) the concentration of porcine enzyme in these supplements (i.e., did the supplements consistently contain 100% of labelled claims for potency or was AE65% variation present?). In our previous systematic review, 2 we excluded randomized cross-over studies from our review. This approach was criticized by reviewers of our previous report, although the use of randomized cross-over studies is problematic because important intra-subject variability has been demonstrated during test-retest studies in the same patient. 3, 4 Furthermore, the FDA's standards for study design in 'Guidance for Industry Exocrine Pancreatic Insufficiency Drug ProductsSubmitting NDAs' 1 strongly discouraged the use of cross-over studies when stating that ''patients should first be stabilized on existing therapy to establish baseline conditions … if baseline conditions are not re-established between treatment periods [in a crossover study], or if treatment in one period carries over into the subsequent period, the results likely will not be interpretable.'' Nevertheless, a complete assessment of the efficacy and safety of pancreatic enzyme supplements should include randomized cross-over trial data.
No previous systematic review has qualitatively and quantitatively reviewed the study design and results of published randomized cross-over trials on the efficacy and safety of these agents. This systematic review utilizes an approach that is similar to our previous systematic review of randomized, parallel-design, trials. 2 We focused on trials that report some measurement of fat absorption, including CFA. We extracted data on study design, malabsorption symptoms such as diarrhoea and weight loss and adverse events. Through this additional systematic review of randomized crossover trials, our aim was to determine if pancreatic enzyme supplements are superior to placebo for improving fat malabsorption and to determine if a specific pancreatic enzyme supplement is superior to other supplements for improving fat malabsorption.
MATERIALS AND METHODS
Literature search
A computer-assisted search was conducted to identify potentially relevant publications in the following databases on 1 . This was then limited to humans and a search filter designed to retrieve controlled clinical trials, systematic reviews, meta-analyses or RCTs was applied.
The same search strategy was used to search the OVID Cochrane Library. Both the MEDLINE In-Process and Other Non-Indexed Citations and the CRD databases were searched using text word combinations. A search of the EMBASE database from 1980 to week 32 of year 2008 was performed using search terms similar to those used in the MEDLINE search.
Study selection criteria. Study inclusion criteria
were: (i) study design-RCT with cross-over design; (ii) study population exocrine pancreatic insufficiency caused by alcohol-associated chronic pancreatitis or CF; (iii) study intervention-pancreatic enzyme supplement [uncoated, enteric coated microspheres (MSP), microspheres (MMSP), microtablets (MT)] vs. placebo or another pancreatic enzyme supplement (Table 1) ; (iv) study endpoint-change in pancreatic malabsorption of fat; and (v) published as full manuscript in English language. We also extracted data regarding clinical symptoms including diarrhoea and weight loss ⁄ gain and adverse events. Studies were excluded if aetiology of malabsorption was nonpancreatic because of bacterial overgrowth, small bowel mucosal disease, short gut, cholestatic liver disease or if patient had secondary pancreatic insufficiency caused by pancreatic cancer ⁄ surgery.
Two investigators (P.S., A.W.) independently reviewed the titles and abstracts of all citations identified by the literature search. Potentially relevant studies were retrieved and the selection criteria were applied. Agreement between investigators for selection of studies for the systematic review was >95% and disagreements were resolved by consensus.
Data extraction and assessment of methodological quality of individual studies. Eligible articles were reviewed in a duplicate, independent manner by two investigators (J.T., T.G.). For each study, the investigators recorded the study design, the inclusion and exclusion criteria, aetiology of primary pancreatic insufficiency, number of patients in each arm of study, age of patients, pancreatic enzyme used, dose of pancreatic enzyme, formulation of pancreatic enzyme, timing of enzyme administration, quantification of faecal fat and its method of collection, results of primary endpoint, results of all secondary endpoints and results of adverse event reporting.
There are no specific criteria to assess the quality of study design for clinical trials about pancreatic enzyme supplementation, although there are validated criteria to quantify the study design quality of RCTs. 5 The Data analysis. Substantial differences in study design, study population, formulation and dosing of enzyme supplements and definition of study endpoint are present across these RCTs. Therefore, pooling of data into a meta-analysis is not feasible and results of individual RCTs are presented in a tabular form.
RESULTS
Literature Search
The MEDLINE search yielded 312 articles. The EM-BASE search yielded 484 articles (Figure 1 ). Manual searches of reference lists from potentially relevant papers identified 13 additional publications that were not detected using the computer-assisted strategy. All citations were downloaded into Reference ManagerÔ and then EndNoteÔ, and duplicates were removed. Seven hundred and sixty unique citations were obtained and the titles and abstracts of each citation were reviewed. Six hundred and sixty-four unique citations were excluded after review of the title and abstract because they were not clinical trials about efficacy of pancreatic enzyme supplementation in patients with exocrine pancreatic insufficiency. Of the remaining 96 citations, 67 were excluded after review of the abstracts because they did not meet inclusion and exclusion criteria, including lack of randomization. Twenty-nine relevant studies were identified, retrieved and completely reviewed. Seventeen studies [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] did not meet study selection criteria because of a variety of exclusion criteria, including inappropriate or incomplete reporting about changes in fat absorption, non-use of cross-over design, or use of inappropriate patient populations. Twelve studies [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] met all inclusion criteria and were available in full manuscript form for inclusion in this systematic review (Table 1) .
Summary of demographic data and methodological quality of trials
Seven studies focused on CF patients 23, 27, [30] [31] [32] [33] [34] while five studies 24-26, 28, 29 primarily enrolled patients with alcohol-related chronic pancreatitis. In the trials examining patients with alcohol-related chronic pancreatitis, fewer than 20% of study patients had idiopathic, familial or unspecified aetiology for chronic pancreatitis (Table 2) . In these studies, results were not stratified between patients with alcohol-associated chronic pancreatitis or chronic pancreatitis from another cause. Also, it is unclear if the patients with alcohol-associated chronic pancreatitis had ongoing alcohol use. The sample size of all studies was quite small with no study enrolling more than 64 patients and over 80% (10 ⁄ 12) of studies enrolled fewer than 40 patients.
In studies with alcohol-associated chronic pancreatitis patients, the mean age of patients clustered around 50 years, whereas the mean age of patients in the CF trials clustered around 10-20 years. The gender distribution was quite disparate in the studies of patients with alcohol-associated chronic pancreatitis with 98 men: 11 women, while the CF trials generally had equal numbers of men and women enrolled in their trials. Only two trials 24, 31 used a placebo control. All remaining studies compared two different pancreatic enzyme supplements or compared two different dosages of the same enzyme supplement. Studies quantified fat malabsorption with CFA or calculated faecal fat excretion (FFE). Most studies (11 ⁄ 12) reported on changes in some gastrointestinal symptoms associated with fat malabsorption, including stool frequency, stool consistency, abdominal discomfort and ⁄ or global symptom improvement, although the reporting was frequently inadequate. The methodological quality of individual trials is summarized in Table 3 . Consistent with the inclusion criteria for this systematic review, all twelve trials used a randomized cross-over technique, although only one study 31 reported using concealed allocation with randomization. Seventy-five percent (nine of 12) of studies were double-blinded, and almost all studies (11 ⁄ 12) had follow-up data for more than 90% of study between the effects of various active treatments detected no difference in CFA or FFE and no consistent difference in weight gain, stool frequency ⁄ consistency or other GI symptoms between different active treatments. Therefore, these studies cannot determine if different dosages of pancreatic enzyme supplements are more or less effective for fat malabsorption and these studies suggest that no specific branded product or specific delivery system is superior for treatment of fat malabsorption in CF patients. However, these studies did not enroll adequate patients to demonstrate non-inferiority and most of these studies for an appropriately designed study (Table 3) , used an appropriate wash-out period per FDA standards 1 and is the only trial of CF patients that provides detailed data on adverse events. This multi-centre study compared Ultrase MT12 to placebo and Ultrase MT20 to placebo in two separate trials. In both trials, patients treated with Ultrase absorbed more protein and fat compared with patients treated with placebo (Table 5) . Detailed adverse event reporting did not identify statistically significant differences in adverse event rates between Ultrase and placebo, although placebo-treated patients had numerically higher rates of flatulence (56% vs. 35%) and abdominal discomfort (57% vs. 23%) compared with Ultrase-treated patients.
Summary of results from trials of alcoholassociated chronic pancreatitis patients
The five studies of alcohol-associated chronic pancreatitis patients 24-26, 28, 29 provide very little data on the efficacy and safety of pancreatic enzyme supplements and only one of these studies 24 is placebo-controlled.
Most studies simply compared pancreatic enzyme supplements that used different delivery systems or different types of pH-sensitive enteric coating 25, 26, 28, 29 while using similar quantities of lipase, amylase, and protease. These studies 25, 26, 28, 29 24, 26 did not report adverse event data and one study 25 provided inadequate adverse event data.
The sole placebo-controlled trial 24 in alcohol-associated chronic pancreatitis patients only enrolled 6 patients and demonstrated that Eurobiol reduced daily FFE by 24% more than placebo (P > 0.05) and Eurobiol 25000 reduced daily FFE by 43% (P < 0.05) more than placebo. Notably, patients in this trial consumed the same number of capsules and hence these data suggest that formulations with higher quantities of pancreatic enzyme produce larger reductions in daily FFE. Delhaye et al. 25 also compared two different delivery systems, Pancrease HL (3 capsules ⁄ day) and Creon (9 capsules ⁄ day), with or without omeprazole. In this 4-arm cross-over trial of 35 patients, faecal fat and protein excretion was similar for each pancreatic supplement. Notably, addition of omeprazole to the enzyme supplement 'was associated with a marked decrease in the fat-protein content ratio, suggesting an improvement in the fat digestive process but a decrease in the efficiency of protein digestion.' Although the authors concluded that the addition of omeprazole did not produce a clinically important impact on fat-protein absorption, the use of omeprazole (or H2 antagonists) is a simple over-the-counter potential treatment options to adjunctively treat fat malabsorption. 35 
DISCUSSION
In 2004, the FDA reported that published RCT data on pancreatic enzyme supplements was insufficient to support their efficacy and safety. 1 Therefore, we performed a systematic review of published paralleldesign RCT data 2 and this systematic review of crossover RCT data to assess this conclusion. Through these reviews, we sought to determine if pancreatic enzyme supplements were superior to placebo for treating fat malabsorption and if a specific pancreatic enzyme supplement appeared to be superior for improving fat malabsorption. Our review found no difference in CFA, FFE, GI symptoms associated with fat malabsorption, or adverse events between different pancreatic enzyme supplements. Most studies reported that CFA was >80% with supplements, and this should be reassuring to physicians and patients using pancreatic enzyme supplements. Based on very limited placebocontrolled trial data (n = 2 trials which studied 65 patients), pancreatic enzyme supplements appear superior to placebo for improving fat malabsorption. However, data are inadequate to determine if these supplements improve symptoms associated with fat malabsorption like steatorrhoea and weight loss. Therefore, published cross-over RCT data do not appear to meet the standard for pivotal Phase III trials that are usually required by the FDA for new products, and the FDA appears justified in concluding that published RCT data are insufficient to support clearly the efficacy and safety of pancreatic enzyme supplements. Our previous systematic review 2 found four welldesigned, parallel-group, placebo-controlled RCTs, which consistently demonstrated that enzyme supplementation improves coefficient of fat malabsorption (CFA) compared to placebo, but fat malabsorption and steatorrhea remained despite enzyme supplementation. These studies also demonstrated that stool frequency and consistency improved with enzyme supplementation, but trials were too brief to demonstrate any changes in weight. However, this systematic review was limited because we excluded cross-over RCTs. None of the randomized, placebo-controlled, paralleldesign studies in our previous review 2 performed a head-to-head comparison of different pancreatic enzyme supplements. We overcome this limitation in our current review and these cross-over RCTs do not demonstrate consistent differences in fat malabsorption or gastrointestinal symptoms between different active treatments. Most studies in this systematic review suffer from substantial methodological limitations that include lack of sample size to demonstrate non-inferiority, lack of a placebo controlled study arm, lack of an appropriate wash-out period between active treatments, lack of detailed reporting on adverse events and poor reporting of 'before treatment' vs. 'after treatment' fat absorption. Randomized cross-over trials can be particularly problematic because important intra-subject variability has been demonstrated during test-retest studies in the same patient. 3, 4 Proper establishment of baseline conditions would probably require standardized quantification of steatorrhoea with dye markers during 72-h stool collection and carefully monitored dietary fat intake. With the exception of one trial, 31 none of the randomized cross-over studies in the current systematic review meets FDA-recommended criteria. Furthermore, studies in this systematic review do not stratify results based on whether patients had alcohol-associated chronic pancreatitis or assess the impact of on-going alcohol use on the effectiveness of pancreatic enzyme therapy. Also, these studies cannot determine if higher dosages of pancreatic enzyme supplements are more effective for fat malabsorption. The methodological limitations of the studies in this systematic review should be addressed in future studies. First, the presence of fat malabsorption should be established with a 72-h faecal fat collection while fat intake is being carefully monitored. This is important because many potentially eligible study patients may not actually have fat malabsorption. In fact, one of the largest (n = 64 patients) parallel-design RCTs 36 demonstrated that over 50% of study patients who used supplements for steatorrhoea actually did not have fat malabsorption after careful testing off supplements. Second, to ensure proper measurement of 72 faecal fat collections, dye markers should be considered to identify the beginning and end of the 72-h stool collection and dietary fat intake could be this review suggests that higher dosages of enzyme supplements are better in reducing fat malabsorption.
In conclusion, our systematic review identified 12 cross-over RCTs on the efficacy and safety of pancreatic enzyme supplementation in patients with exocrine pancreatic insufficiency. None of these trials provides data on stability of enzyme preparations over 12 months, bioavailability, or batch-to-batch consistency in quantity of enzyme supplement per capsule, which is currently recommended by the FDA. The two placebo-controlled RCTs do demonstrate that enzyme supplements are superior to placebo for improvement in fat absorption, and most RCTs demonstrated that CFA was >80% with pancreatic enzyme supplements. The published trials do not demonstrate any consistent differences between different supplements with respect to improvement in fat malabsorption or adverse events. Data are inadequate to determine if escalating dosages of enzyme supplements produce incremental improvements in fat malabsorption.
